{"filing":{"accession_number":"0001411690-26-000036","cik":"0001411690","ticker":"BNGO","company_name":"Bionano Genomics, Inc.","form":"8-K","filing_date":"2026-06-05","report_date":null,"primary_document":"bngo-20260602.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1411690/000141169026000036/bngo-20260602.htm"},"events":[{"id":3722,"run_id":3264,"accession_number":"0001411690-26-000036","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Alka Chaubey, Ph.D., Chief Medical Officer of Bionano Genomics, resigned effective July 5, 2026. This is a clear departure of a named executive officer disclosed under Item 5.02, and the departure of a CMO—a senior leadership position—is material to investors' assessment of the company's medical and scientific direction.","company_name":"Bionano Genomics, Inc.","ticker":"BNGO","filing_date":"2026-06-05","items":[{"id":4730,"accession_number":"0001411690-26-000036","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Alka Chaubey, Ph.D., Chief Medical Officer of Bionano Genomics, resigned effective July 5, 2026. This is a clear departure of a named executive officer disclosed under Item 5.02, and the departure of a CMO—a senior leadership position—is material to investors' assessment of the company's medical and scientific direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T20:01:14.380724+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4730,"accession_number":"0001411690-26-000036","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Alka Chaubey, Ph.D., Chief Medical Officer of Bionano Genomics, resigned effective July 5, 2026. This is a clear departure of a named executive officer disclosed under Item 5.02, and the departure of a CMO—a senior leadership position—is material to investors' assessment of the company's medical and scientific direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T20:01:14.380724+00:00","company_name":"Bionano Genomics, Inc.","ticker":"BNGO","filing_date":"2026-06-05"}]}